MONMOUTH JUNCTION, N.J. - April 26, 2020 - A journal article by Biotech Support Group, with co-authors from Vanderbilt University Medical Center and Rutgers Proteomics Center, describes new strategies for proteomic investigation of blood components.
Citation is:
Kuruc M, Zheng H, Sowerhardy A, Avadhani S, Roy D, et al. (2020) New Strategies to Categorize Blood for Proteomic Biomarker Discovery (https://www.scitcentral.com/article.php?journal=53&article=1416&article_title=New%20Strategies%20to%20Categorize%20Blood%20for%20Proteomic%20Biomarker%20Discovery#tabs2). Proteomics Bioinformatics, 2(2): 90-107.
We draw upon BSG's knowledgebase of proteome information reportable after using depletion or enrichment products in LC-MS/MS workflows and how this knowledge can be utilized in new strategies for biomarker discovery from blood samples. We note that BSG's products have simply and efficiently reduced the complexity of the serum proteome allowing for cost-effective workflows. Finally, we discuss how patterns of Serpins, a superfamily of protease inhibitors, may serve as a surrogate measure of the progressive stages of the innate immune systems' response to both infectious and noninfectious disease.
Swapan Roy, Ph.D., President and Founder of Biotech Support Group, concurs stating "Proteomics started with annotation and Venn diagrams but now the field demands robust quantitation. This has been our focus; how to address quantitative differences between proteins in blood samples representing a challenge or disease state, vs. samples representing a normal or control state. Ultimately, biomarkers derived from blood provides the most useful clinically actionable biomarkers so that is why our product line is focused on all blood compartments, both cellular and extracellular. We argue in this report for characterization of the innate immune response, as proteins derived from it imparts a wide range of effects in infectious and non-infectious disease. The innate response proteome also is in the sweet spot of LC-MS analysis. Furthermore, an over-exuberant innate immune response is now one of the challenges the world faces with COVID-19 induced acute respiratory distress syndrome (ARDS). We hope with the strategies described in this report, we can find and develop biomarkers to not only better characterize disease but provide a better understanding of how the innate immune response becomes dysregulated in chronic disease, with consequences for acute disease. From this, we hope to gain further insight so that healthcare professionals can develop new and sometimes repurpose approved therapies, to address many diseases; COVID-19 being one of many with a highly engaged inflammatory component.
For more information on the BSG complete line of Albumin & IgG Removal products, visit: https://www.biotechsupportgroup.com/Articles.asp?ID=451
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group (BSG) develops methods for cost effective and efficient sample prep essential for these expanding markets.
For more information, go to http://www.biotechsupportgroup.com (https://www.biotechsupportgroup.com/Default.asp). For business development, contact Matt Kuruc at mkuruc@biotechsupportgroup.com
Contact
Biotech Support Group LLC
